herbal-diabetes-2017-keynote

6 / 7

Volume 8, Issue 10 (Suppl) J Diabetes Metab
ISSN: 2155-6156 JDM, an open access journal Herbal Diabetes 2017
November 02-04, 2017
Page 28
Notes:
conferenceseries.com
November 02-04, 2017 Bangkok, Thailand
23rd International Conference on
Herbal and Alternative Remedies for
Diabetes and Endocrine Disorders
Evidences that insulin resistance, core of cardiometabolic diseases, is the primary therapeutic target
C ardiometabolic diseases affect about one third of the worldwide population. Recent years revealed that the core of these
different pathologies is insulin resistance. Diminished sensitivity to insulin leads to various metabolic and vascular (both
macro- and microvascular) disturbances. Epidemiology and clinical observations show that resistance to this hormone can be
seen very early, possibly already in early childhood. It has clear-cut impacts on adult health and worsens with aging, however
also aging-related diseases such as cognitive dysfunction and related dementias are also associated with resistance to insulin.
The presentation will show the poorly recognized importance of microvascular insulin resistance as well as many aspects
of this defect in various tissues. It will also be shown how to detect this parameter easily and early in human beings. Finally
suggestions will be made about possible new treatment strategies.
Biography
Nicolas F Wiernsperger is a French Physiologist and Pharmacologist. He has been Head of Research Department on Cerebrovascular Accidents at Novartis,
Switzerland until 1984. He established as a world recognized Specialist of Microcirculation. From 1985 to 2005, he was appointed as the Head of International
Pharmacological Development and Senior Pharmacologist at Merck KgA in Lyon. He was also the Head of a private/public research unit on Diabetes Microvascular
Complications at Lyon University. He is an international recognized expert of cardiometabolic diseases and aging. He has published nearly 150 papers as well as
2 books. He has been teaching as Invited Professor at several universities. Since 2005, he deals with the development of new drugs as well as, more recently,
nutraceuticals.
Nicolas F Wiernsperger
University of Lyon, France
Nicolas F Wiernsperger, J Diabetes Metab 2017, 8:10 (Suppl)
DOI: 10.4172/2155-6156-C1-071